A Pharmacodynamic Comparison of Prasugrel vs. High-Dose Clopidogrel in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

DSpace/Manakin Repository

A Pharmacodynamic Comparison of Prasugrel vs. High-Dose Clopidogrel in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

Citable link to this page

. . . . . .

Title: A Pharmacodynamic Comparison of Prasugrel vs. High-Dose Clopidogrel in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
Author: Angiolillo, Dominick J.; Badimon, Juan Jose; Saucedo, Jorge F.; Jakubowski, Joseph A.; Zhu, Baojin; Ojeh, Clement K.; Baker, Brian A.; Effron, Mark B.; Frelinger, Andrew Lawrence; Michelson, Alan D

Note: Order does not necessarily reflect citation order of authors.

Citation: Angiolillo, Dominick J., Juan Jose Badimon, Jorge F. Saucedo, Andrew L. Frelinger, Alan D. Michelson, Joseph A. Jakubowski, Baojin Zhu, Clement K. Ojeh, Brian A. Baker, and Mark B. Effron. 2011. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European Heart Journal 32(7): 838-846.
Full Text & Related Files:
Abstract: Aims: Patients with diabetes mellitus (DM) have increased platelet reactivity and reduced platelet response to clopidogrel compared with patients without DM. Prasugrel, a more potent antiplatelet agent, is associated with greater reductions in ischaemic events compared with clopidogrel, particularly in patients with DM. The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM. Methods and results: Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 was a prospective, randomized, double-blind, crossover study in patients with type 2 DM and coronary artery disease (CAD). Patients (n= 35) were randomly assigned to either prasugrel 60 mg loading dose (LD)/10 mg maintenance dose (MD) or clopidogrel 600 mg LD/150 mg MD over two 1-week treatment periods separated by a 2-week washout period. Platelet function was assessed by VerifyNow® P2Y12 assay, light transmission aggregometry, and vasodilator-stimulated phosphoprotein phosphorylation at 0, 1, 4, and 24 h and 7 days. Greater platelet inhibition by VerifyNow® P2Y12 was achieved by prasugrel compared with clopidogrel at 4 h post-LD (least squares mean, 89.3 vs. 27.7%, P< 0.0001; primary endpoint). The difference in platelet inhibition between prasugrel and clopidogrel was significant from 1 h through 7 days (P < 0.0001). Similar results were obtained using all other platelet function measures. Prasugrel resulted in fewer poor responders at all time points irrespective of definition used. Conclusion: In patients with type 2 DM and CAD, standard-dose prasugrel is associated with greater platelet inhibition and better response profiles during both the loading and maintenance periods when compared with double-dose clopidogrel.
Published Version: doi:10.1093/eurheartj/ehq494
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069388/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:5358879

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters